Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP. Chua C, et al. Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408. doi: 10.1007/s00280-015-2811-y. Epub 2015 Jun 24. Cancer Chemother Pharmacol. 2015. PMID: 26099969 Clinical Trial.
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Ng HHM, et al. Among authors: tai d. J Immunother Cancer. 2020 Aug;8(2):e000987. doi: 10.1136/jitc-2020-000987. J Immunother Cancer. 2020. PMID: 32847986 Free PMC article.
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Tai D, et al. Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035. doi: 10.1016/S2468-1253(21)00305-8. Epub 2021 Oct 23. Lancet Gastroenterol Hepatol. 2021. PMID: 34695377 Clinical Trial.
Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC.
Tan AC, Seet AOL, Lai GGY, Lim TH, Lim AST, Tan GS, Takano A, Tai DWM, Tan TJY, Lam JYC, Ng MCH, Tan WL, Ang MK, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim WT, Tan EH, Lim TKH, Tan DSW. Tan AC, et al. J Thorac Oncol. 2020 Dec;15(12):1928-1934. doi: 10.1016/j.jtho.2020.08.011. Epub 2020 Aug 28. J Thorac Oncol. 2020. PMID: 32866654 Free article.
Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Gemcitabine plus Cisplatin for Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial.
Chan SL, Chotipanich C, Choo SP, Kwang SW, Mo F, Worakitsitisatorn A, Tai D, Sundar R, Ng DCE, Loke KSH, Li L, Ng KKC, Peng YW, Yu SC. Chan SL, et al. Among authors: tai d. Liver Cancer. 2022 Jun 15;11(5):451-459. doi: 10.1159/000525489. eCollection 2022 Sep. Liver Cancer. 2022. PMID: 36158588 Free PMC article.
Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience.
Seet AOL, Tan AC, Tan TJ, Ng MCH, Tai DWM, Lam JYC, Tan GS, Gogna A, Too CW, Tan BS, Takano A, Lim A, Lim TH, Lim ST, Dent RA, Ang MK, Yap YS, Tan IBH, Choo SP, Toh CK, Lim EH, Farid M, Skanderup AJ, Iyer NG, Lim WT, Tan EH, Lim TKH, Tan DSW. Seet AOL, et al. JCO Precis Oncol. 2021 May 18;5:PO.20.00261. doi: 10.1200/PO.20.00261. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34250396 Free PMC article.
461 results